Loading clinical trials...
Loading clinical trials...
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Conditions
Interventions
Eflornithine
Lomustine
+1 more
Locations
79
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Kaiser Permanente
Los Angeles, California, United States
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
Kaiser Permanente Center
Redwood City, California, United States
Start Date
July 1, 2016
Primary Completion Date
June 1, 2023
Completion Date
June 1, 2023
Last Updated
January 21, 2022
NCT05839379
NCT05084430
NCT05956821
NCT04780009
NCT04978727
NCT02101905
Lead Sponsor
Orbus Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions